Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. Its primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
Phone650-574-3000
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$22.13 billion
Profitability
Miscellaneous
Employees11,000
Next Earnings Date5/2/2019 (Confirmed)
OptionableOptionable
Gilead Sciences (NASDAQ:GILD) Frequently Asked Questions
What is Gilead Sciences' stock symbol?
Gilead Sciences trades on the NASDAQ under the ticker symbol "GILD."
How often does Gilead Sciences pay dividends? What is the dividend yield for Gilead Sciences?
Gilead Sciences announced a quarterly dividend on Monday, February 4th. Shareholders of record on Friday, March 15th will be paid a dividend of $0.63 per share on Thursday, March 28th. This represents a $2.52 dividend on an annualized basis and a dividend yield of 4.01%. The ex-dividend date is Thursday, March 14th. This is an increase from Gilead Sciences's previous quarterly dividend of $0.57. View Gilead Sciences' Dividend History.
How were Gilead Sciences' earnings last quarter?
Gilead Sciences, Inc. (NASDAQ:GILD) released its quarterly earnings data on Monday, February, 4th. The biopharmaceutical company reported $1.44 earnings per share for the quarter, missing analysts' consensus estimates of $1.70 by $0.26. The biopharmaceutical company earned $5.80 billion during the quarter, compared to analyst estimates of $5.52 billion. Gilead Sciences had a return on equity of 37.03% and a net margin of 24.65%. The firm's revenue was down 2.6% compared to the same quarter last year. During the same quarter last year, the business earned $1.78 earnings per share. View Gilead Sciences' Earnings History.
When is Gilead Sciences' next earnings date?
How can I listen to Gilead Sciences' earnings call?
Gilead Sciences will be holding an earnings conference call on Thursday, May 2nd at 4:30 PM Eastern. Interested parties can register for or listen to the call using this link.
What price target have analysts set for GILD?
19 Wall Street analysts have issued 1-year price targets for Gilead Sciences' shares. Their forecasts range from $68.00 to $95.00. On average, they anticipate Gilead Sciences' stock price to reach $81.9375 in the next year. This suggests a possible upside of 30.3% from the stock's current price. View Analyst Price Targets for Gilead Sciences.
What is the consensus analysts' recommendation for Gilead Sciences?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Gilead Sciences in the last year. There are currently 7 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Gilead Sciences.
What are Wall Street analysts saying about Gilead Sciences stock?
Here are some recent quotes from research analysts about Gilead Sciences stock:
- 1. According to Zacks Investment Research, "Gilead’s HIV franchise maintains momentum, driven by continued uptake of Genvoya and Odefsey, and the rapid adoption of Biktarvy. However, the company’s HCV franchise continues to witness a slowdown across key markets, including the United States and Europe, as a result of competition and pricing pressure. Consequently, Gilead shifted focus to its HIV franchise, and newer avenues like CAR-T therapy and NASH. However, the company suffered a setback with the failure of a late-stage study on selonsertib in patients with compensated cirrhosis (F4) due to NASH. Shares have underperformed the industry in the past six months." (4/23/2019)
- 2. Maxim Group analysts commented, "Gilead and Galapagos NV (GLPG – NR) reported positive data from two P3 studies of JAK1 inhibitor filgotinib in treating rheumatoid arthritis (RA); FINCH-1 and FINCH-3. Recall the FINCH-2 trial read-out in 3Q18. All three trials met their primary endpoints as well as multiple secondary endpoints." (3/29/2019)
- 3. Mizuho analysts commented, "We spoke to GILD. The company was able to confirm the title and time, and it noted that yes, this this is the pivotal DISCOVER trial, but couldn’t say exactly what data we will get. The company also confirmed that it’s a late-breaker and also an oral presentation. Clinicaltrials.gov still shows an active" status, but GILD noted to us that in general (not necessarily specific to this particular Descovy entry) clincaltrials.gov results can be presented at a lag. We note that oral presentations typically need to be informative, can’t just be baseline data, etc … our best guess is we’re getting both efficacy and safety data." (2/26/2019)
- 4. Cantor Fitzgerald analysts commented, ": We are increasing our price target to $88 from $87 and reiterating our Overweight rating. Gilead beat top and bottom line consensus expectations as the Biktarvy launch remains strong in HIV. Our price target is higher by $1/share given revenue trends were slightly more robust than we projected. The company also increased its product revenue guidance to $20.8-21.3B from $20-21B. Product revenues were $5.45B and EPS were $1.84/share. Biktarvy beat expectations by ~$50M, as it reported revenues of $375M. GILD has also benefited from a generic Letairis not entering the market, and it doesn’t expect an entrant in 2018. We have updated our estimates for the quarter." (10/26/2018)
Has Gilead Sciences been receiving favorable news coverage?
News coverage about GILD stock has trended somewhat negative recently, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Gilead Sciences earned a media sentiment score of -1.4 on InfoTrie's scale. They also assigned news articles about the biopharmaceutical company a news buzz of 2.0 out of 10, indicating that recent media coverage is very unlikely to have an impact on the stock's share price in the immediate future.
Who are some of Gilead Sciences' key competitors?
Some companies that are related to Gilead Sciences include Amgen (AMGN), Biogen (BIIB), NOVOZYMES A/S/S (NVZMY), Seattle Genetics (SGEN), Qiagen (QGEN), bluebird bio (BLUE), Neurocrine Biosciences (NBIX), BIO-TECHNE (TECH), Spark Therapeutics (ONCE), China Biologic Products (CBPO), argenx (ARGX), Ablynx (ABLYF), Allogene Therapeutics (ALLO), Repligen (RGEN) and Halozyme Therapeutics (HALO).
What other stocks do shareholders of Gilead Sciences own?
Who are Gilead Sciences' key executives?
Gilead Sciences' management team includes the folowing people:
- Daniel O'Day, Chairman & Chief Executive Officer
- Robin L. Washington, CFO, Principal Accounting Officer & Executive VP
- John G. McHutchison, Chief Scientific Officer
- Brett A. Pletcher, Secretary, Chief Compliance Officer & Executive VP
- William A. Lee, Executive Vice President-Research
Who are Gilead Sciences' major shareholders?
Gilead Sciences' stock is owned by many different of retail and institutional investors. Top institutional investors include First Manhattan Co. (0.16%), PGGM Investments (0.13%), Confluence Investment Management LLC (0.09%), Mondrian Investment Partners LTD (0.09%), Retirement Systems of Alabama (0.08%) and Factory Mutual Insurance Co. (0.07%). Company insiders that own Gilead Sciences stock include Gayle E Wilson, Gregg H Alton, James R Meyers, John C Martin, John F Milligan, John Francis Cogan, Richard James Whitley and Robin L Washington. View Institutional Ownership Trends for Gilead Sciences.
Which major investors are selling Gilead Sciences stock?
GILD stock was sold by a variety of institutional investors in the last quarter, including Avalon Advisors LLC, First Manhattan Co., Ferguson Wellman Capital Management Inc., LaFleur & Godfrey LLC, Busey Wealth Management, DNB Asset Management AS, First Hawaiian Bank and First National Bank of Mount Dora Trust Investment Services. Company insiders that have sold Gilead Sciences company stock in the last year include Gayle E Wilson, John C Martin, John Francis Cogan and Richard James Whitley. View Insider Buying and Selling for Gilead Sciences.
Which major investors are buying Gilead Sciences stock?
GILD stock was acquired by a variety of institutional investors in the last quarter, including Factory Mutual Insurance Co., Pacer Advisors Inc., Mondrian Investment Partners LTD, Manning & Napier Group LLC, PGGM Investments, Mercer Global Advisors Inc. ADV, Underhill Investment Management LLC and Gofen & Glossberg LLC IL. View Insider Buying and Selling for Gilead Sciences.
How do I buy shares of Gilead Sciences?
Shares of GILD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Gilead Sciences' stock price today?
One share of GILD stock can currently be purchased for approximately $62.87.
How big of a company is Gilead Sciences?
Gilead Sciences has a market capitalization of $80.19 billion and generates $22.13 billion in revenue each year. The biopharmaceutical company earns $5.46 billion in net income (profit) each year or $6.15 on an earnings per share basis. Gilead Sciences employs 11,000 workers across the globe.
What is Gilead Sciences' official website?
How can I contact Gilead Sciences?
Gilead Sciences' mailing address is 333 LAKESIDE DRIVE, FOSTER CITY CA, 94404. The biopharmaceutical company can be reached via phone at 650-574-3000 or via email at [email protected]
MarketBeat Community Rating for Gilead Sciences (NASDAQ GILD)
MarketBeat's community ratings are surveys of what our community members think about Gilead Sciences and other stocks. Vote "Outperform" if you believe GILD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GILD will underperform the S&P 500 over the long term. You may vote once every thirty days.
